MedTrace Logo

Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath

NCT01246336 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2017-10-31

No results posted yet for this study

Summary

Parkinson's disease is diagnosed clinically, because biomarkers that may help in diagnosis and differential diagnosis are not yet available. Exhaled breath testing may yield a "breath-print" that can be used to distinguish healthy and diseased states.

Conditions

Interventions

OTHER

collection of exhaled breath

no intervention

Sponsors & Collaborators

  • Technion, Israel Institute of Technology

    collaborator OTHER

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Ilana Schlesinger, MD · Rambam Health Care Campus

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2012-01-31
Completion
2012-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01246336 on ClinicalTrials.gov